17,261 trials
Anaplastic Thyroid Cancer · Recurrent Thyroid Cancer
Primary: Confirmed Response Rate (Partial Response [PR] or Complete Response [CR]) Per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 Criteria — 13 percentage of…
Type II Refractory Celiac Disease (RCD-II) · In-situ Small Bowel T-cell Lymphoma
Primary: Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes — 2.45; 7.30 percent…
Asthma
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 3; 4; 4; 4 participants
Head and Neck Neoplasms · Lung Neoplasms · Urinary Bladder Neoplasms
Primary: Progression-free Survival (PFS) — 2.3; 3.7; 3.6; 1.7 months
Leukemia, Myeloid, Acute
Primary: Number of Participants Who Achieved Composite Complete Response (CRc) (Intent-to-Treat Population) — 18; 18 Participants
Mitochondrial Myopathy
Primary: Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT) — 13.5; 36.5; 64.5; 20.4 meters
Non-small Cell Lung Cancer Stage IV
Primary: Progression Free Survival Rate — 4; 0 Participants
Glucose Intolerance
Primary: Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for Meal Tolerance Test (MTT) at Week 8 — -2.42; -9.52…
HIV-1 Infection
Primary: Percentage of Participants Achieving HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL of Plasma at Week 48 — 100.0 Percentage of Participants
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination 1 — 7.3; 3.6; 3.6; 3.2 percentage of participants
Induction of Labor Affected Fetus / Newborn
Primary: Time From Beginning of Induction to Delivery — 13.8; 14.3 hours
Chronic Pain · Diabetic Neuropathies · Diabetes Mellitus
Primary: Change in Average Pain Intensity. — -2.24; -2.28; -2.56; -2.79 units on a scale — p=0.0621
EGFR Exon 19 Deletion Mutation · EGFR NP_005219.2:p.L858R · Lung Non-Squamous Non-Small Cell Carcinoma
Primary: Progression Free Survival (PFS) — 13.5; 17.9 months — p=0.39
Pulmonary Arterial Hypertension
Primary: Number of Participants Reporting at Least One Treatment-Emergent Adverse Event (TEAE) — 18 Participants
Autism Spectrum Disorder · ASD · Autism
Primary: Change in Social Communication as Measured by the Vineland Adaptive Behavior Scales, Third Edition (VABS-3) — 3.13; 1.98 score on a scale — p=0.83